ADCT Stock Summary and Trading Ideas (Adc Therapeutics SA Common Shares | NYSE:ADCT)

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Adc Therapeutics SA Common Shares trades on the NYSE stock market under the symbol ADCT.

As of August 21, 2026, ADCT stock price climbed to $1.00 with 1,036,192 million shares trading.

ADCT has a beta of 3.34, meaning it tends to be more sensitive to market movements. ADCT has a correlation of 0.09 to the broad based SPY ETF.

ADCT has a market cap of $127.23 million. This is considered a Micro Cap stock.

Last quarter Adc Therapeutics SA Common Shares reported $19 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $101,200 and exceeded earnings estimates by $.10.

In the last 3 years, ADCT traded as high as $6.04 and as low as $.36.

The top ETF exchange traded funds that ADCT belongs to (by Net Assets): IWM, IWN, IBB, VTWO, IWC.

ADCT has underperformed the market in the last year with a price return of -67.9% while the SPY ETF gained +21.7%. ADCT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -70.7% and -11.8%, respectively, while the SPY returned +3.4% and -1.0%, respectively.

ADCT support price is $.91 and resistance is $1.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADCT shares will trade within this expected range on the day.